These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36238308)

  • 21. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
    Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
    In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
    Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
    CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nakai Y; Nakayama M; Nonomura N; Uemura M
    Anticancer Res; 2021 Nov; 41(11):5811-5816. PubMed ID: 34732455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
    Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
    Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
    Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
    In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature.
    Liu C; Piao J; Shang Z
    BMC Urol; 2021 Mar; 21(1):42. PubMed ID: 33743675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
    Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
    Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.
    Salgia NJ; Bergerot PG; Maia MC; Dizman N; Hsu J; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
    Eur Urol; 2020 Oct; 78(4):498-502. PubMed ID: 32828600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
    Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
    Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developments in personalized therapy for metastatic renal cell carcinoma.
    Fujiwara R; Kageyama S; Yuasa T
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade.
    Takeda M; Kashima S; Fuchigami Y; Yoshino T; Kataoka TR; Yamasaki T; Kagamu H; Kobayashi T; Akamatsu S
    Front Immunol; 2022; 13():934991. PubMed ID: 35865543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of palliative surgery for bone metastasis of metastatic renal cell carcinoma in the era of targeted therapy.
    Hara H; Kawamoto T; Fukase N; Sawada R; Fujiwara S; Yahiro S; Miyamoto T; Terakawa T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
    Eur J Surg Oncol; 2023 May; 49(5):928-933. PubMed ID: 36463006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report.
    Shirotake S; Umezawa Y; Okabe T; Kaneko GO; Kanao K; Nishimoto K; Oyama M
    In Vivo; 2020; 34(3):1475-1480. PubMed ID: 32354949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
    Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
    Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.